edecesertib (GS-5718) / Gilead  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
edecesertib (GS-5718) / Gilead
NCT05165771: Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment

Withdrawn
2
0
NA
GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg, XELJANZ®, Placebo to match Tofacitinib
Gilead Sciences
Rheumatoid Arthritis
02/23
03/23
NCT05629208: Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Recruiting
2
33
Europe, US, RoW
Edecesertib, GS-5718, Edecesertib Placebo
Gilead Sciences
Cutaneous Lupus Erythematosus (CLE)
12/24
12/24

Download Options